Dasakast 50 TABLETS Dasakast-50 contains Dasatinib, an oral multi-kinase inhibitor that targets BCR-ABL kinase and Src family kinases (SRC, LCK, YES, FYN). It binds to both the active and inactive conformations of the BCR-ABL kinase domain with higher potency than imatinib, inhibiting leukemic cell proliferation and inducing apoptosis. It is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as Ph+ CML and Ph+ acute lymphoblastic leukemia (ALL) resistant or intolerant to prior therapy.